Medicinal drugs and driving: from research to clinical practice

European Commission (2001) White Paper European Transport Policy for 2010: Time to Decide, Office for Official Publications of the European Comunities, Luxembourg

1999, Conclusions and recommendations, 319

Directorate General for Energy and Transport (2002) Report on Drugs, Medicines and Driving, Directorate General for Energy and Transport, Brussels

European monitoring centre for drugs and drug addiction (1999) Literature Review on the Relation Between Drug Use, Impaired Driving and Traffic Accidents (CT.97.EP.14), EMCDDA, Lisbon (http://www.emcdda.org/multimedia/project_reports/finalreportdrugsanddriving.pdf)

De Gier, 1999, Review of investigations of prevalence of illicit drugs in road traffic in different European Countries, 13

De Gier, J.J. (2002) Problems Raised by the Use of Psychoactive Drugs by Drivers, Pompidou Group, Council of Europe, Strasbourg, P-PG/Circrout (2002) 2 rev. (http://www.coe.int/T/E/Social%5FCohesion/pompidou%5Fgroup/5%2EPublications/List_of_publications/2002_2EREVCIR%20web.asp#TopOfPage)

1985, Drug concentration and driving impairment, J. Am. Med. Assoc., 254, 2618, 10.1001/jama.1985.03360180122038

Río, 2001

O′Hanlon, 1986, Performance testing as part of new drug registration, 311

Patat, 1998, Driving, drug research and the pharmaceutical industry, Hum. Psychopharmacol. Clin. Exp., 13, S124, 10.1002/(SICI)1099-1077(1998110)13:2+<S124::AID-HUP48>3.0.CO;2-H

Anonymous (1995) Guidelines on psychotropic drugs for the EC. Clinical investigation of medicinal products in the treatment of generalized anxiety disorder, panic disorder and obsessive-compulsive disorder. Eur. Neuropsychopharm. 5, 151–155 (http://pharmacos.eudra.org/F2/eudralex/vol-3/pdfs-en/3cc28aen.pdf)

Shamsi, 2000, Sedation and antihistamines: a review of inter-drug differences using proportion impairment ratios, Hum. Psychopharmacol. Clin. Exp., 15, S3, 10.1002/1099-1077(200010)15:1+<::AID-HUP247>3.0.CO;2-S

Riedel, 1998, Mechanims of drug induced driving impairment: a dimensional approach, Hum. Psychopharmacol. Clin. Exp., 13, S49, 10.1002/(SICI)1099-1077(1998110)13:2+<S49::AID-HUP49>3.0.CO;2-1

Barbone, 1998, Association of road-traffic accidents with benzodiazepine use, Lancet, 352, 1331, 10.1016/S0140-6736(98)04087-2

Neutel, 1998, Benzodiazepine-related traffic accidents in young and elderly drivers, Hum. Psychopharmacol. Clin. Exp., 13, S115, 10.1002/(SICI)1099-1077(1998110)13:2+<S115::AID-HUP56>3.0.CO;2-O

Hering, 1994

De Gier, 1998, Drugs and driving research: application of results by drug regulatory authorities, Hum. Psychopharmacol. Clin. Exp., 13, S133, 10.1002/(SICI)1099-1077(1998110)13:2+<S133::AID-HUP47>3.0.CO;2-I

Alvarez, F.J. et al. (2001) Prescribing and Dispensing Guidelines for Medicinal Drugs Affecting Driving Performance, International Council on Alcohol, Drugs and Traffic Safety, Utrecht (http://raru.adelaide.edu.au/icadts/reports/ICADTSpresguiderpt.pdf)

Toxicological Society of Belgium and Luxembourg asbl (1999) Influence des Médicaments sur les Capacités de Conduire. Toxicological Society of Belgium and Luxembourg asbl, Bruxelles (http://www.ibsr.be/fr/534info.htm)

Krüger, 1999, Overview of legal provisions, difficulties faced by police, and analysis of prevention attemps in selected european countries, 63